192 related articles for article (PubMed ID: 31253937)
1. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
Chen Y; Bi X; Zhang F; Sun Z; Xu P; Jiang H; Lu W; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Chem; 2020 Aug; 101():103991. PubMed ID: 32559581
[TBL] [Abstract][Full Text] [Related]
3. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
[TBL] [Abstract][Full Text] [Related]
4. Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay.
Lu T; Hu JC; Lu WC; Han J; Ding H; Jiang H; Zhang YY; Yue LY; Chen SJ; Jiang HL; Chen KX; Chai HF; Luo C
Acta Pharmacol Sin; 2018 Sep; 39(9):1544-1552. PubMed ID: 29795359
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
6. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
7. Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.
Suryanarayanan V; Singh SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4303-4319. PubMed ID: 29228881
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract][Full Text] [Related]
9. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
[TBL] [Abstract][Full Text] [Related]
12. Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation.
Park S; Stanfield RL; Martinez-Yamout MA; Dyson HJ; Wilson IA; Wright PE
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5335-E5342. PubMed ID: 28630323
[TBL] [Abstract][Full Text] [Related]
13. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
[TBL] [Abstract][Full Text] [Related]
14. GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).
Romero FA; Murray J; Lai KW; Tsui V; Albrecht BK; An L; Beresini MH; de Leon Boenig G; Bronner SM; Chan EW; Chen KX; Chen Z; Choo EF; Clagg K; Clark K; Crawford TD; Cyr P; de Almeida Nagata D; Gascoigne KE; Grogan JL; Hatzivassiliou G; Huang W; Hunsaker TL; Kaufman S; Koenig SG; Li R; Li Y; Liang X; Liao J; Liu W; Ly J; Maher J; Masui C; Merchant M; Ran Y; Taylor AM; Wai J; Wang F; Wei X; Yu D; Zhu BY; Zhu X; Magnuson S
J Med Chem; 2017 Nov; 60(22):9162-9183. PubMed ID: 28892380
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Selective Small-Molecule Inhibitors for the ENL YEATS Domain.
Ma XR; Xu L; Xu S; Klein BJ; Wang H; Das S; Li K; Yang KS; Sohail S; Chapman A; Kutateladze TG; Shi X; Liu WR; Wen H
J Med Chem; 2021 Aug; 64(15):10997-11013. PubMed ID: 34279931
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
[TBL] [Abstract][Full Text] [Related]
17. Rational design of cyclic peptide modulators of the transcriptional coactivator CBP: a new class of p53 inhibitors.
Gerona-Navarro G; Yoel-Rodríguez ; Mujtaba S; Frasca A; Patel J; Zeng L; Plotnikov AN; Osman R; Zhou MM
J Am Chem Soc; 2011 Feb; 133(7):2040-3. PubMed ID: 21271695
[TBL] [Abstract][Full Text] [Related]
18. Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain.
Spiliotopoulos D; Zhu J; Wamhoff EC; Deerain N; Marchand JR; Aretz J; Rademacher C; Caflisch A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2472-2478. PubMed ID: 28410781
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
